Om

Mabwell (Shanghai) Bioscience Co., Ltd. is an innovation-driven biopharmaceutical company with integrated capabilities spanning research and development, manufacturing, and commercialization. The company operates an extensive pipeline of innovative therapies, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars targeting oncology, immunology, and other therapeutic areas. Mabwell's commercial portfolio includes Albipagrastim alfa for Injection, a novel granulocyte colony-stimulating factor developed using albumin long-acting fusion technology, and biosimilar products targeting RANKL and TNF-α indications. The company's research engine is powered by proprietary platforms including its IDDC platform and B-lymphocyte screening technology. Mabwell maintains a global development strategy through collaborations with international partners, including licensing agreements with companies for development and commercialization rights in specific regions. The company serves patients globally by developing and delivering therapies aimed at addressing significant unmet medical needs across multiple disease areas.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I MABWELL SHANGHAI BIOSCIENCE CO MED ENDAVU: Køb Mabwell Shanghai Bioscience Co ($2493) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Mabwell Shanghai Bioscience Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.